Since 2010, Fewer Prostatectomies Being Performed for Lowest-Risk Prostate Cancer
By Elana Gotkine HealthDay Reporter
TUESDAY, May 13, 2025 -- Since 2010, there has been a decrease in the proportion of prostatectomies that are pathologic grade group 1 (pGG1), according to a study published online April 28 in JAMA Oncology.
Steven M. Monda, M.D., from the University of Michigan in Ann Arbor, and colleagues examined trends in pathologic grade on prostatectomy as a surrogate for overtreatment in a retrospective cohort study. The grade of prostate cancer on final pathology reports was examined among patients undergoing prostatectomy between Jan. 1, 2010, and Sept. 1, 2024, in two cohorts (162,558 patients in the Surveillance, Epidemiology, and End Results [SEER] cohort and 23,370 patients in the Michigan Urological Surgery Improvement Collaborative [MUSIC] statewide clinical registry). The primary outcome was the proportion of all prostatectomies that were pGG1.
The researchers found that in SEER and in MUSIC, there were decreases in the proportion of radical prostatectomies resulting in pGG1 on final pathology reports, from 32.4 to 7.8 percent from 2010 to 2020 and from 20.7 to 2.7 percent from 2012 to 2024, respectively. While controlling for age and race, within SEER and MUSIC, a more recent prostatectomy was associated with a lower likelihood of pGG1 prostatectomy (odds ratios per five years, 0.41 and 0.39, respectively). A more recent prostatectomy was associated with the presence of a higher-risk preoperative feature within a subset analysis of those prostatectomies that were final pGG1.
“The decrease in the number of surgeries for low-grade prostate cancer shows that active surveillance helps,” Monda said in a press release. "Routine PSA (prostate-specific antigen) checks, MRIs (magnetic resonance imaging) and biopsies can ensure that prostate cancer doesn't progress to a condition that requires treatment.”
One author disclosed ties to the medical technology industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted May 2025
Read this next
Canagliflozin Tied to Reduction in HbA1c in Children, Teens With T2DM
WEDNESDAY, Aug. 6, 2025 -- Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c (HbA1c) for children and adolescents with type 2 diabetes mellitus...
About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease
WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...
Follow-Up on Blood-Based Colorectal Cancer Screening Results Is Low
TUESDAY, Aug. 5, 2025 -- Just under half of patients receiving an abnormal blood-based colorectal cancer screening test result receive a follow-up colonoscopy (FU-CY) within...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.